雌激醇会影响高血糖微环境中的穆勒质细胞和内皮细胞反应,具有高级糖化最终产品
Natalia Castro1, Juan S Peña1, Richard Cliver2
1Rutgers, The State University of New Jersey, Department of Biomedical Engineering, USA.
Experimental eye research
|November 30, 2024
概括
在糖尿病视网膜病变模型中,雌激醇补充剂降低了氧化应激,并加强了内部血视网膜屏障. 这一发现凸显了雌醇在糖尿病患者的视力保护方面的潜力.
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 细胞生物学 细胞生物学
背景情况:
- 糖尿病视网膜病变是视力丧失的主要原因,不成比例地影响雌激素减少的女性.
- 内血视网膜屏障 (iBRB) 对于神经保护至关重要,其完整性受到糖尿病诱导的高级糖化终产物 (AGEs) 的损害.
研究的目的:
- 在超血糖症的体外模型中研究补充性雌激醇对细胞反应和屏障功能的保护作用.
- 评估雌激素在糖尿病条件下如何影响米勒细胞和内皮细胞.
主要方法:
- 使用了模拟高血糖和AGE暴露的体外模型.
- 测量了细胞形态,活性氧物种 (ROS) 水平和超内皮电阻 (TEER).
- 穆勒质细胞和内皮细胞被用或不用补充雌激素治疗.
主要成果:
- 在高血糖条件下,补充雌醇显著降低了Müller glia中的ROS水平.
- 雌激素增强了穆勒质细胞和内皮细胞层的屏障抵抗力.
- 观察到雌激醇对结合内皮细胞和穆勒质细胞屏障的修复作用.
结论:
- 雌激醇表明,在内血液视网膜屏障中,对高血糖引起的损伤起着保护作用.
- 补充雌激醇可能提供一种治疗策略,用于在糖尿病视网膜病变中保护视力.
更多相关视频
06:26Analyzing the Permeability of the Blood-Brain Barrier by Microbial Traversal through Microvascular Endothelial Cells
Published on: February 14, 2020
15.3K
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
12.1K
相关概念视频
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
